Diagnosis rate impact by condition among female GLP-1 utilizers of Mounjaro, Ozempic, Wegovy, and Zepbound during first 24 months compared to control Note: All comparisons are at a 99% confidence interval Inpatient admission by condition among female GLP-1 utilizers of Mounjaro, Ozempic, Wegovy, and Zepbound during first 24 months compared to control Note: All comparisons are at a 99% confidence interval The Importance of Adherence Across both diabetes and weight loss cohorts, adherence to GLP-1 therapy at 80% or higher amplifies cost benefits
Baicalein protects rat insulinoma INS-1 cells from palmitate-induced lipotoxicity by inducing HO-1
Both anti-diabetic treatments function by playing key modulatory roles in the incretin system
The increasing rates of obesity and diabetes in the United States are driving this growth, with Centers for Disease Control and Prevention data indicating more than 100 million US adults are obese
Advanced glycation end products: key mediator and therapeutic target of cardiovascular complications in diabetes
like a watered-down sports drink without any flavour